Tag: Cancer: Leukemia
Dasatinib Tops Imatinib for Ph+ Acute Lymphoblastic Leukemia
Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
Improvement in median overall survival from 5.8 years in 1995 to 2011 to not reached in 2009 to 2017
Risk Score Developed to Help ID Heart Failure Risk in Leukemia
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Testosterone Replacement May Benefit Younger Male Cancer Survivors
Benefits include significant improvement in body composition measurements over six months
Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Elevated risk stronger in women than men; risk for non-Hodgkin lymphoma increased in patients ≤45
Risk for Second Primary Malignancy Up in CLL Survivors
SPM risk higher for men and nonwhites, after chemotherapy, for recent years of diagnosis, for advanced age
Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML
Overall survival significantly longer, percentage of remission higher than with salvage chemotherapy
Exercise Intolerance May Harm Neurocognition in ALL Survivors
Exercise intolerance tied to impaired neurocognition in adult survivors of childhood ALL
Factors Predict Low BMD in Pediatric Blood Cancer Survivors
Low bone mineral density detected during guideline-recommended dual-energy X-ray absorptiometry
Severe Adverse Cardiovascular Events Associated With Ibrutinib
Risk up for severe, sometimes fatal, events, including supraventricular arrhythmias, CNS events
